



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## NOS1-IN-1

<b>Cat. No.:</b>	HY-130452
<b>CAS No.:</b>	357965-99-2
<b>Molecular Formula:</b>	C <sub>14</sub> H <sub>24</sub> F <sub>9</sub> N <sub>7</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	589.37
<b>Target:</b>	NO Synthase
<b>Pathway:</b>	Immunology/Inflammation
<b>Storage:</b>	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



## BIOLOGICAL ACTIVITY

<b>Description</b>	NOS1-IN-1 is a selective and cell-permeable nNOS inhibitor with a K <sub>i</sub> of 120 nM. NOS1-IN-1 exhibits 2617-fold and 325-fold selectivity over eNOS (K <sub>i</sub> =39 μM) and iNOS (K <sub>i</sub> =325 μM), respectively <sup>[1]</sup> . NOS1-IN-1 can be used for the research of neurological disease, including cerebral palsy (CP) <sup>[2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Ki: 120 nM (nNOS) <sup>[1]</sup>

## REFERENCES

- [1]. J M Hah, et al. Reduced amide bond peptidomimetics. (4S)-N-(4-amino-5-[aminoalkyl]aminopentyl)-N'-nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase. *J Med Chem.* 2001 Aug 2;44(16):2667-70.
- [2]. Haitao Ji, et al. Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. *Ann Neurol.* 2009 Feb;65(2):209-17.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA